S&P 500 7,609.78 +0.13% NASDAQ 27,093.90 +0.03% DOW 51,307.79 +0.45% R2K 2,931.96 +0.90% VIX 15.77 -1.74%
Next Bullish Trade
ABT Abbott Laboratories NYQ
$86.97 -0.81 (-0.92%)
Neutral · -0.41σ

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $11.2B $1.1B $1.3B $0.9B 9.6% 12.0%
2025-12-31 $11.5B $1.8B $2.3B $2.6B 15.5% 19.6%
2025-09-30 $11.4B $1.6B $2.1B $2.3B 14.5% 18.1%
2025-06-30 $11.1B $1.8B $2.1B $1.5B 16.0% 18.4%
2025-03-31 $10.4B $1.3B $1.7B $0.9B 12.8% 16.3%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-04-16 1.15 1.15 +0.3%
2026-01-22 1.50 1.49 +0.3%
2025-10-15 1.30 1.30 +0.1%
2025-07-17 1.01 0.99 +1.9%
2025-04-16 0.76 0.78 -2.6%
2025-01-22 1.34 1.34 -0.2%
2024-10-16 1.21 1.20 +0.8%
2024-07-18 1.14 1.10 +3.2%
2024-04-17 0.98 0.95 +2.8%
2024-01-24 1.19 1.19 +0.0%
2023-10-18 1.14 1.10 +3.7%
2023-07-20 1.08 1.05 +2.9%
2023-04-19 1.03 0.99 +4.3%
2023-01-25 1.03 0.94 +9.7%
2022-10-19 1.15 0.94 +22.9%
2022-07-20 1.43 1.14 +25.3%
2022-04-20 1.73 1.46 +18.1%
2022-01-26 1.32 1.21 +9.5%
2021-10-20 1.40 0.95 +47.9%
2021-07-22 1.17 1.02 +14.9%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
LLY $949B 37.7 23.9 13.1 27.3 30.5 82.8% 55.5% 169.9% 0.96%
UNH $343B 28.5 18.1 0.8 18.5 3.5 18.8% 2.0% 0.7% 5.15%
JNJ $537B 25.8 17.5 5.6 16.6 6.6 68.0% 9.9% -52.9% 2.33%
MRK $286B 32.6 12.1 4.3 11.2 6.2 76.7% 4.9% 4.92%
ABBV $381B 105.6 13.3 6.1 14.8 -57.2 72.0% 12.4% -46.2% 5.47%
PFE $146B 19.5 9.0 2.3 7.8 1.6 74.8% 5.4% -10.1% 8.50%
TMO $179B 26.5 17.7 4.0 19.4 3.4 40.9% 6.2% 11.3% 3.08%
ABT $151B 24.4 14.3 3.4 15.2 2.9 56.5% 7.8% -19.7% 4.19%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 35.31%

HolderShares% out
Blackrock Inc. 145,687,458 8.36%
Vanguard Capital Management LLC 112,949,933 6.48%
State Street Corporation 79,575,468 4.57%
Capital Research Global Investors 49,775,362 2.86%
Vanguard Portfolio Management LLC 47,944,891 2.75%
Charles Schwab Investment Management 45,500,055 2.61%
Geode Capital Management, LLC 39,148,795 2.25%
Capital International Investors 37,498,227 2.15%
Morgan Stanley 30,101,596 1.73%
Wellington Management Group, LLP 27,070,518 1.55%

Insider activity · 90d

No insider trades for ABT in last 90d.

Analyst estimates

yfinance
Low
$92.0
Mean
$117.29167
High
$135.0
Analysts
24

Consensus: buy (mean 1.66667). Distribution requires FINNHUB_API_KEY.

SEC filings

FormFiled DescriptionAction
4 2026-04-29 Insider transaction (Form 4) view ·
10-Q 2026-04-29 10-Q view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-27 Insider transaction (Form 4) view ·
8-K 2026-04-27 FORM 8-K view ·
8-K 2026-04-17 FORM 8-K view ·
8-K 2026-04-16 8-K view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-03-25 Insider transaction (Form 4) view ·
8-K 2026-03-23 FORM 8-K view ·
DEF 14A 2026-03-13 DEFINITIVE PROXY STATEMENT view ·
8-K 2026-03-09 FORM 8-K view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
8-K 2026-02-26 FORM 8-K view ·
8-K 2026-02-20 FORM 8-K view ·
10-K 2026-02-20 10-K view ·
4 2026-02-06 Insider transaction (Form 4) view ·
4 2026-01-26 Insider transaction (Form 4) view ·
8-K 2026-01-22 8-K view ·
4 2026-01-05 Insider transaction (Form 4) view ·
4 2026-01-05 Insider transaction (Form 4) view ·
4 2026-01-05 Insider transaction (Form 4) view ·
4 2026-01-05 Insider transaction (Form 4) view ·
4 2025-12-12 Insider transaction (Form 4) view ·
8-K 2025-12-12 FORM 8-K view ·
4 2025-11-25 Insider transaction (Form 4) view ·

About

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood ga…